XML 16 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Income Statement [Abstract]        
Molecular diagnostic testing $ 183.9 $ 182.6 $ 348.9 $ 354.5
Pharmaceutical and clinical services 12.6 10.7 25.0 22.3
Total revenue 196.5 193.3 373.9 376.8
Costs and expenses:        
Cost of molecular diagnostic testing 37.4 34.1 71.6 65.0
Cost of pharmaceutical and clinical services 7.0 6.5 12.7 12.1
Research and development expense 18.6 16.7 38.0 33.9
Selling, general, and administrative expense 120.3 90.8 232.2 177.3
Total costs and expenses 183.3 148.1 354.5 288.3
Operating income 13.2 45.2 19.4 88.5
Other income (expense):        
Interest income 0.3 0.1 0.6 0.2
Interest expense (2.6) (0.1) (3.3) (0.1)
Other 1.2 (0.2) (0.6)  
Total other income (expense): (1.1) (0.2) (3.3) 0.1
Income before income tax 12.1 45.0 16.1 88.6
Income tax provision 6.2 7.9 11.4 21.1
Net income 5.9 37.1 4.7 67.5
Net income attributable to non-controlling interest 0.0 0.0 0.0 0.0
Net income attributable to Myriad Genetics, Inc. stockholders $ 5.9 $ 37.1 $ 4.7 $ 67.5
Earnings per share:        
Basic $ 0.09 $ 0.53 $ 0.07 $ 0.97
Diluted $ 0.09 $ 0.50 $ 0.07 $ 0.92
Weighted average shares outstanding:        
Basic 68.2 70.5 68.5 69.6
Diluted 68.3 73.8 68.9 73.1